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Thereisanincreasedprevalenceofcardiovasculardisease-(CVD-)relatedmortalityinpatientswithchronickidneydisease(CKD).
Endothelial dysfunction is a primary event in the development of atherosclerosis and hypertension and likely contributes to the
elevated cardiovascular risk in CKD. Endothelial dysfunction has been shown to occur in the peripheral vasculature of patients
with both severe and moderate CKD. Mechanisms include oxidative stress, L-arginine deﬁciency, and elevated plasma levels of
ADMA. Interventions designed to restore vascular function in patients with CKD have shown mixed results. Evidence from cell
culture studies suggest that the accumulation of uremic toxins inhibits L-arginine transport and reduces nitric oxide production.
The results of these studies suggest that endothelial dysfunction may become less reversible with advancing kidney disease. The
purpose of this paper is to present the current literature pertaining to potential mechanisms of peripheral vascular dysfunction in
chronic kidney disease and to identify possible targets for treatment.
1.Introduction
Chronic kidney disease (CKD) is a major public health
concern aﬀecting nearly 20 million people in the United
States alone [1]. Patients with CKD are at greater risk
of cardiovascular disease- (CVD-) related morbidity and
mortality than individuals without CKD with similar car-
diovascular risk factors and tend to die before reaching
end-stage renal disease (ESRD) [2–5]. Treatments aimed
solely at reducing traditional cardiovascular risk factors do
not improve cardiovascular function in patients with late-
stage CKD [6]. Therefore, traditional CVD risk factors alone
cannot explain the high incidence of CVD in CKD.
Endothelial dysfunction is a precursor to the develop-
ment of atherosclerosis [7, 8] and has been shown to be
associated with increased cardiovascular risk in patients with
left ventricular dysfunction and congestive heart failure [9–
11]. The combination of traditional risk factors in CKD
is not enough to explain the high incidence of CVD and
endothelial dysfunction has been suggested to play a role
in the increased CV risk in CKD [12, 13]. In support of
this, a longitudinal study of patients with end-stage renal
disease(ESRD)foundallcausemortalitytobeindependently
associated with impaired endothelial function [14].
The majority of studies of endothelial function in renal
disease havefocused onESRDand patientsreceiving dialysis;
however, little is known about endothelial function in
earlier stages of CKD. Guidelines from the Kidney Disease
Outcomes Quality Initiative (K/DOQI) place patients with
CKD into one of ﬁve stages based on glomerular ﬁltration
rate (GFR) and are presented in Table 1 [1, 15]. The risk of
developingCVD canbe predicted from GFR and increases as
GFR declines[3].These guidelinesmake it easierto delineate
diﬀe r e n c e si nv a s c u l a rf u n c t i o ni nC K Dp a t i e n t sw i t hl o w
to moderate renal deﬁciency; however to date those data are
limited.Withthemajorityofpatientsdyingofcardiovascular
disease before needing dialysis, there is an urgent need for
investigations into vascular function in earlier stagesofCKD.
A great deal of literature has described the role of vascular
calciﬁcation and aortic stiﬀness in promoting atherosclerosis
in CKDand havebeenreviewed elsewhere [16]. The purpose
ofthispaperistopresentasummary oftheavailableresearch
regarding mechanisms of peripheral vascular dysfunction
throughout the progression of chronic kidney disease.2 Cardiology Research and Practice
Table 1: Stages of CKD.
Stage Description GFR, mL·min−1 per
1.73m2
1 Kidney damage with
normalor increased GFR
≥90
2 Kidney damage with mildly
decreased GFR 60–89
3 Moderately decreased GFR 30–59
4 Severely decreased GFR 15–29
5K i d n e y f a i l u r e <15 or dialysis
Adapted from National KidneyFoundation K/DOQI clinicalpracticeguide-
lines for chronic kidney disease [15].
2.VascularFunctioninCKD
The vascular endothelium consists of a single layer of cells
lining the interior lumen of blood vessels. Aside from
functioning as a barrier between the intravascular space
and the interstitum, the vascular endothelium works as an
important regulator of vascular homeostasis. Perhaps one
of the most important functions of the endothelium is the
synthesis and release of the vasodilator nitric oxide [17].
Nitric oxide is produced from the amino acid substrate L-
arginine by the enzyme endothelial nitric oxide synthase
(eNOS) [18]. Activation of eNOS requires the binding of the
cofactor tetrahydrobiopterin (BH4) as well as the presence
of Ca2+/Calmodulin for the synthesis of NO [19]. NO
diﬀuses through the basal membrane of the endothelial cell
into the smooth muscle where it activates the conversion
of GTP to cyclic GMP by soluble guanylyl cyclase (sGC)
signaling smooth muscle relaxation and vasodilation [20].
Thispathwayoccursinresponsetomechanicalshearstressor
the binding of bradykinin or acetylcholine to their receptors
on endothelial cells and is vi t a lf o rp r o p e rc o n t r o la n d
maintenance of blood pressure. Additionally, nitric oxide
plays an important role by regulating vascular permeability,
leukocyte adhesion [21], and smooth muscle proliferation
[22], all of which play an important role in maintaining
cardiovascular health [23]. Endothelial dysfunction is char-
acterized by a reduced synthesis or bioavailability of NO
and is a primary event in the development of atherosclerosis
[24]. In vivo assessment of conduit artery and microvascular
function through ﬂow-mediated dilation (FMD) and venous
occlusion plethysmography (VOP) have been used to assess
vascular function in CKD (Table 2) and serve as measures of
endothelial function.
Endothelial dysfunction is present in CKD and may
explain the increased cardiovascular risk in these patients.
Urinary nitrate and nitrite (NOx) excretion, an index
of total body NO production, is lower in patients with
ESRD and likely contributes to the hypertension observed
in these patients [36]. Endothelial dysfunction has been
shown to occur in vitro in human microvessels obtained
via subcutaneous fat biopsies from patients receiving dialysis
or renal replacement surgery [37]a sw e l la sin vivo in the
forearm microvasculature of predialysis CKD patients using
venousocclusionplethysmography[28].Further,endothelial
dysfunction has been shown to occur in conduit vessels
upstream of the microvasculature [27, 34]. Thus, endothelial
dysfunction appears to be characteristic of CKD.
The confounding eﬀects of other risk factors in CKD
make it diﬃcult to diﬀerentiate whether the source of
endothelial dysfunction is due to renal impairment or
the combination of multiple risk factors. Studies using
children with CKD have assessed endothelial function before
atherosclerosisandotherassociatedriskfactorswerebelieved
to occur[38–40].Endothelial-dependentdilation was shown
to be impaired in children with chronic renal failure using
ﬂow-mediateddilation(FMD)suggestingthatkidneydisease
alone leads to the development of endothelial dysfunction
[38]. Additionally, nitric oxide plays an important role in
attenuating renal impairment and may slow the progression
ofCKDinpatientswithmildrenalimpairment.ReducedNO
bioavailability has been shown to contribute to glomerular
hypertension and accelerate renal damage leading to more
rapid progression of CKD [41]. While the presence of
endothelial dysfunction is well documented in CKD, the
mechanisms have not yet been fully explained.
3.PotentialMechanisms ofEndothelial
Dysfunction in CKD
3.1. Oxidative Stress. One of the most widely studied con-
tributors to endothelial dysfunction is oxidative stress [42].
Oxidative stress is deﬁned by a disruption in the balance
between free radical production and removal by endogenous
antioxidants [43]. Oxidative stress impairs NO signaling
pathways in endothelial cells and contributes to endothelial
dysfunction [43]. Oxidative stress is present in patients
with moderate to severe CKD [32, 44]a sw e l la sp a t i e n t s
with ESRD or receiving hemodialysis [32, 45]. Endothelial
dysfunction worsens with progressive loss of renal function
and is associated with a variety of markers of oxidative stress
includinglipidhydroperoxides,oxidizedglutathione,protein
carbonyls and F2-isoprostanes [29, 31, 44, 45]a sw e l la s
reduced antioxidant capacity [46, 47].
Markers of oxidative stress are inversely correlated with
endothelial function in patients with CKD. In one study,
brachial-artery ﬂow-mediated dilation was decreased in
hemodialysis patients and correlated to increased levels of
TBARS, a marker of lipid peroxidation [33]. Interestingly,
these patients lacked overt symptoms of cardiovascular
disease suggesting that oxidative stress may contribute to
the early progression of endothelial dysfunction in CKD.
Endothelial function and GFR have also been shown to
be associated with increased levels of advanced glycation
end products (AGEs) in diﬀerent stages of predialysis,
nondiabetic CKD, likely through increased abundance of
AGE receptors (RAGE) on the surface of endothelial cells
[48]. AGEs have been shown to increase inﬂammation and
oxidative stress [48] and can also inhibit eNOS activity
directly as well as reduce substrate bioavailability by reacting
with L-arginine resulting in endothelial dysfunction [49].
The mechanisms behind the contribution of oxidative
stress in endothelial dysfunction in CKD appear to occur
primarily through eNOS and NO dependent pathwaysCardiology Research and Practice 3
Table 2: Summary of studies measuring in vivo endothelial function in adult patients with CKD.
Study Reported degree of
CKD Method Finding
Yilmaz et al. [25] Stage 1 FMD Improved following 12-week treatment with ramipril
Yilmaz et al. [26] Stage 1–4 FMD Improved following 3-month treatment with ramipril or valsartan
Nanayakkara et al. [27]C C r = 38 ± 15 FMD Improvement following 18-month stepwise treatment with pravastatin,
vitamin E, and homocysteinie lowering therapy
Annuk et al. [28]C C r = 29.4 ± 24.0 VOP Impaired and related to degree of renal impairment
Annuk et al. [29]C C r = 25.1 ± 16.2 VOP Impairments correlated to markers of oxidative stress
Annuk et al. [30]S e r u m C r = 287 ± 143 VOP Improved by acute COX inhibition or L-arginine treatment
Annuk et al. [31] Stage 3–5 VOP Negatively correlated to levels of lipid hydroperoxides (LOOH)
Ghiadoni et al. [32] Stage 3–5,
hemodialysis FMD Acute vitamin C infusion restored impaired function in hemodialysis
but not in CKD
Costa-Hong et al. [33]E S R D F M D Plasma TBARS levels associated with impaired endothelial-dependent
dilation in patients without symptoms of CVD
Cross et al. [34] Predialysis
hemodialysis VOP, FMD Acute infusion of vitamin C improves endothelium-dependent dilation
in forearm resistance vasculature but not in brachial artery
Cross et al. [35] Predialysis,
hemodialysis VOP, FMD Local or systemic L-arginine infusion did not improve resistance or
endothelial-dependent dilation
FMD = ﬂow-mediated dilation; VOP = venous occlusion plethysmography; CCr = creatinine clearance (mL/min/1.73m2); Serum Cr = serum creatinine
(µmol/L).
(Figure 1). Cross et al. [34] observed a reduction in
acetylcholine-induced forearm bloodﬂow (venousocclusion
plethysmography) in predialysis patients with ESRD (GFR
<20mLmin). This impairment was ameliorated when the
antioxidant vitamin C was infused through the brachial
artery suggesting that the source of endothelial dysfunction
was oxidative stress. This improvement was abolished when
vitamin C was infused with the NOS inhibitor L-NMMA
suggestingthat the eﬀectofoxidativestress onforearm blood
ﬂow is NO dependent. Interestingly, vitamin C did not cause
an improvement in endothelial function in larger upstream
conduit vessels as assessed by brachial and radial artery ﬂow-
mediated dilation in both predialysis and dialysis patients
with severe renal failure [34]. This ﬁnding suggests that some
other mechanism contributes to endothelial dysfunction in
late-stage kidney disease.
Although oxidative stress has been shown to be more
severe in hemodialysis patients than in patients with stage
3–5 CKD [32], studies have shown oxidative stress to con-
tribute to endothelial dysfunction earlier in CKD. Perfused
mesenteric arteries from rats that underwent renal mass
reduction have impaired vasodilation in response to acetyl-
choline within 3–10daysaftersurgery [50].This impairment
was restored by incubation with the antioxidant enzyme
superoxide dismutase (SOD) [50] suggesting that oxidative
stress also plays a role in endothelial dysfunction early in
the progression of CKD. In human patients with moderate
renal impairment, the forearm blood ﬂow response to an
arterial infusion of methacholine was attenuated [29]. These
same patients also demonstrated increased levels of lipid
hydroperoxides (LOOH) and an increased ratio of oxidized
to reduced glutathione (GSSG/GSH). These markers of
oxidative stress were correlated to both serum creatinine
and forearm blood ﬂow suggesting that oxidative stress
eNOS
NO
L-arginine
ONOO− BH4
Endothelial cell
O2−
Figure 1: Simpliﬁed schematic depicting mechanisms by which
reactive oxygen species can reduce nitric oxide (NO) availability.
NO is synthesized from eNOS and can combine with excess
superoxide (O2−)f r o mv a s c u l a ro x i d a s e st of o r mp e r o x y n i t r i t e
(ONOO−) limiting NO availability. Superoxide can also oxidize the
eNOS cofactor tetrahydrobiopterin (BH4), uncoupling eNOS and
reducing NO synthesis.
contributes to endothelial dysfunction in humans with
moderate CKD.
Supplementation with antioxidants has been shown to
reduce cardiovascular events in CKD and hemodialysis [51].
In the Secondary Prevention with Antioxidants of Cardio-
vascular Disease in Endstage Renal Disease (SPACE) trial,
hemodialysis patients receiving 800IU/day of vitamin E had
signiﬁcantly fewer primary cardiovascular end-points than
placebo-treated controls [52]. The beneﬁts of antioxidant
therapy have also been studied in earlier stages of CKD
and have been shown to improve endothelial function. The
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study demonstrated that antioxidant treatment in patients
with mild to moderate renal impairment was eﬀective
at improving brachial artery ﬂow-mediated dilation [27].
Patients underwent three stages of drug treatment consisting
of treatment with pravastatin, vitamin E, and homocysteine-
lowering therapy introduced consecutively at 6 month
intervals. Additionally, this improvement in endothelial
functionoccurreddespiteaprogressivelossinrenalfunction.
Antioxidant treatment has not been eﬀective at reducing
cardiovascular risk in other diseases [53]; however, these
studies suggest that the use of antioxidants in CKD may be
an exception.
Another strategy for combating oxidative stress medi-
ated endothelial dysfunction may be bolstering endogenous
antioxidant defense mechanisms. Endogenous antioxidant
enzymesplayanimportant rolein preventingoxidativestress
and are impaired in CKD. Plasma and erythrocyte levels
of glutathione peroxidase (GSH-px), superoxide dismutase
(SOD), and catalase were shown to be signiﬁcantly lower
in predialysis patients with ESRD compared to healthy
control subjects [46]. Endogenous antioxidants have also
been shown to be lower in earlier stages of CKD with
levels of erythrocytic GSH-px, and SOD impaired as early
as stage 1 (GFR <90mL/min) [45]. Treatments aimed at
improving the endogenous antioxidant defense systems may
be more eﬀective than antioxidant therapy. Chronic exercise
training was shown to reduce levels of ROS and improve
endothelial-dependentrelaxation in5/6nephrectomized rats
[54]. Exercise has been shown to improve endothelial-
dependent dilation in aging [55] and may help prevent the
progression of endothelial dysfunction in CKD; however,
further study is needed.
The role of oxidative stress on vascular function in CKD
is well documented however more research is needed to
uncover the sources and speciﬁc targets of free radicals.
The production of the powerful radical superoxide from
NADPH oxidases is a likely contributor oxidative stress in
the endothelium [43] and can combine with NO to form
reactive nitrogen species such as peroxynitrite (ONOO−)
(Figure 1). Peroxinitrite formation reduces the bioavailibilty
of NO and contributes to nitrositive cellular damage. Vaziri
et al. [56] measured increased nitrotyrosine abundance, a
marker of nitrositive protein modiﬁcation, in aorta, heart,
liver, and plasma of 5/6 nephrectomized rats. Nitrotyrosine
levels were decreased to normal levels in rats treated with
the antioxidant vitamin E. Angiotensin II is elevated in CKD
and has been shown to activate NADPH oxidases [57]. Few
studies have examined the role of inhibition of the renin-
angiotensin system on endothelial-dependent dilation in
CKD. One study observed improved FMD following short-
term ACE-inhibition in patients with stage 1 diabetic CKD
[25]. Additional free radical production may occur from
xanthineoxidase;however,theroleofthisenzymeinhumans
with CKD is not well known. Treatment with the xanthine
oxidaseinhibitorallopurinol slowed theprogression ofCKD,
and reduced cardiovascular risk in patients with CKD(eGFR
<60mL/min) [58]; however, it is unclear if these beneﬁcial
eﬀects were due to decreased oxidative stress or reduced
serum uric acid levels.
Oxidation of the essential eNOS cofactor tetrahydro-
biopterin (BH4) has been shown to cause uncoupling of
eNOS (Figure 1). Once uncoupled, eNOS itself becomes
a source of superoxide contributing to further oxidative
damage [59, 60]. Chronic treatment with BH4 has been
shown to lower systolic blood pressure and reduce pro-
teinuria in 5/6 nephrectomized rats [61]. In another study,
endothelial-dependent relaxation of aortic rings from 5/6
nephrectomized rats was restored in isolated vessels treated
with BH4 [62]. These vessels were also associated with
increased superoxide production which was ameliorated
by treatment with L-NAME suggesting that the source
of oxidative stress was uncoupled eNOS. The presence of
oxidative stress in CKD is well deﬁned and is a contribut-
ing factor to the development of endothelial dysfunction.
Treatments aimed at restoring vascular redox balance may be
eﬀective at reducing cardiovascular risk in CKD. In addition,
supplementation with BH4 in humans with CKD may pre-
vent eNOS uncoupling and reduce oxidative stress.
3.2. L-Arginine Deﬁciency. Nitric oxide synthesis relies on
the amino acid substrate L-arginine. L-arginine synthesis
primarily occurs in the proximal tubules of the renal cortex
and is impaired with loss of functional renal mass [41].
Despite reduced production, the plasma concentration of
L-arginine in patients with CKD appears to be maintained
at normal levels [63]. The maintenance of plasma L-arginine
levels in CKD may be a consequence of increased amino acid
release into the blood due to skeletal muscle wasting [64],
and impaired L-arginine transport due to increased uremic
toxins [65, 66]. Both mechanisms could potentially mask the
decreaseinL-arginine productionbymaintaining theplasma
concentrations.
TheintracellularconcentrationofL-arginine inendothe-
lial cells is normally much higher than the Km of eNOS
for L-arginine [67]. Despite the apparent cellular abundance
of substrate, exogenous treatment with L-arginine has been
eﬀective at restoring endothelial function in other disease
states including aging [68] and hypercholesterolemia [69,
70]. Cooke et al. [69] demonstrated that endothelial-
dependent relaxation of aortic rings was restored in hyper-
cholesterolemic rabbits pretreated with an intravenous infu-
sion of L-arginine. In 5/6 nephrectomized rats, both chronic
and acute treatment with L-arginine improved blood pres-
sure and restored endothelial-dependent relaxation of aortic
rings [62]. This phenomenon, referred to as the “arginine
paradox” [67, 71], was not observed, however, in patients
receiving dialysis or in predialysis patients with severe renal
failure [35]. In another study, infusion of L-arginine into
the forearm improved the endothelial-dependent dilatory
response to methacholine in both patients with CKD and
aged-matched controls [30]. Agemay have beena confound-
ing factor in this study, however, since subjects were between
50 and 80 years of age.
L-arginine transport has been shown to be impaired
by uremic toxins and may potentially explain why L-
arginine treatment has beenineﬀectiveinlaterstagesofCKD
(Figure 2). Endothelial cells cultured in uremic plasma had
a reduced ability to transport L-arginine into the cells [65].Cardiology Research and Practice 5
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Figure 2: Potential mechanisms of L-arginine deﬁciency in chronic
kidney disease (CKD). Asymmetric dimethylarginine (ADMA) is
a competitive inhibitor of eNOS and ADMA levels are increased
in CKD. Synthesis of ADMA occurs via protein arginine methyl-
transferase (PRMT) which may exhibit increased expression and
activity in CKD. Expression of the enzyme dimethylarginine
dimethylaminohydrolase (DDAH) may be decreased in CKD
resulting in reduced degradation of ADMA. L-arginine transport
into endothelial cells can be inhibited by increased levels of
uremic toxins as disease progresses and result in reduced substrate
availability for NO production.
When the same experiment was repeated with cells cultured
in a synthetic solution containing uremic levels of urea,
the same result was observed indicating that urea is an
important inhibitor of L-arginine transport. The transport
of L-arginine occurs through the cationic amino acid
transporter CAT-1. Urea transport occurs through urea
transporters (UT) that appear to be colocalized with CAT-1
in endothelial cells [66]. The movement of urea into the
cell appears to be required in order to inhibit L-arginine
transport.Thismechanismmayoccurwiththeaccumulation
of uremic toxins as seen in CKD and lead to impaired L-
arginine transport and reduced substrate available for NO
synthesis.
The uremic inhibition of L-arginine transport appears
to occur in an “all-or-nothing” fashion [41, 65]. Inhibition
of L-arginine transport was only eﬀective with a synthetic
solution of urea at or above 15mmol/L and not eﬀective
at lower concentrations [65]. Interestingly, when uremic
plasma was diluted to achieve a lower urea concentration
below this threshold, L-arginine transport was still inhibited.
This suggests that other uremic toxins also contribute to
transport inhibition and should be studied more extensively
in order to elucidate their mechanisms.
Hyperhomocysteinemia reduced L-arginine uptake
in cultured endothelial cells and impaired endothelial-
dependent relaxation in homocysteine-treated vessels
and was associated with oxidative stress and increased
nitrotyrosine levels [72]. Treatment with vitamin C
restored cellular uptake of L-arginine while L-arginine
treatment improved endothelial-dependent relaxation
of aortic rings. CAT-1 expression was also attenuated in
homocysteine-treated cells and was related to impaired NO
production with no change in eNOS expression or activity.
Hyperhomocysteinemia is present in patients with CKD [4]
and may contribute to the uremic inhibition of L-arginine
transport in humans; however, this has not been studied.
The accumulation of uremic toxins in the plasma occurs
progressively with loss of renal function. Increased levels of
urea inhumanshasbeencorrelatedtodecreasedendothelial-
dependent dilation [31] and may be related to reduced L-
arginine transport. While L-arginine treatment has been
ineﬀective at later stages of CKD and during hemodialysis,
it is plausible that treatment in earlier stages, when the
inﬂuence of uremic toxins is not as robust, may be eﬀective
at restoring endothelial function.
3.3. ADMA in CKD. Another potential contributor to
endothelial dysfunction in CKD is the formation of the
endogenous NOS inhibitors asymmetric dimethylarginine
(ADMA) and N-monomethylarginine (L-NMMA) [73, 74].
ADMA and L-NMMA are the result of posttranscriptional
methylation of L-arginine residues by protein arginine
methyltransferases (PRMTs) and are released in their free
form following protein hydrolysis. ADMA production is
about 10-fold that of L-NMMA a n di se l e v a t e di np a t i e n t s
with chronic renal failure [75]. Plasma levels of ADMA
predict progression to ESRD in patients with CKD [76]a n d
ultimately predict adverse cardiovascular events in patients
with mild to moderate CKD [77, 78]. ADMA is associated
with impaired endothelial function in healthy adults [79],
and has been shown to be inversely correlated to brachial
artery FMD in patients with proteinuria and amyloidosis
[26].
A D M Ah a sb e e nc l a s s i ﬁ e da sa“ u r e m i ct o x i n ”a n d
exhibits adversecardiovascular eﬀects[4].Inhealthysubjects
infused with ADMA, heart rate and cardiac output were
reduced while mean arterial pressure increased [80]. ADMA
has also been linked to impaired endothelial function.
Brachial artery FMD was impaired in healthy individuals
treated with L-NMMA suggesting that a reduction in the
ratio or L-arginine to methylated arginines competitively
inhibits NO production in vivo [35]. The addition of
L-arginine in these patients improved this balance and
restored endothelial function. While L-arginine treatment
is an eﬀective strategy in restoring substrate balance and
combating ADMA and L-NMMA in other disease models,
its eﬀectiveness in CKDis questionabledue to the L-arginine
transport issues discussed above. It is therefore important to
explorealternativestrategiesforreducingcirculatinglevelsof
ADMA in kidney disease.
Interventions designed to lower ADMA production or
increase ADMA clearance may be eﬀective at improving
endothelial function in CKD. Clearance of ADMA in the
urine is impaired with renal damage and contributes to
elevated plasma concentrations [81]; however, this is not
the primary reason for elevated ADMA in CKD. Urinary
clearance of ADMA did not explain elevations in plasma
ADMA in an animal model of CKD [82]. Instead, increased
PRMT activity and expression and reduced degradation
of ADMA by dimethylarginine dimethylaminohydrolase
(DDAH) are likely the major causes of increased ADMA
in CKD [41]( Figure 2). PRMT expression and activity is6 Cardiology Research and Practice
increased in the presence of oxidized LDL cholesterol and
results in increased production of ADMA in endothelial cells
[83]. Antioxidant therapy with vitamin E has been shown
to reduce ADMA levels in patients with CKD [84]a n d
may be an eﬀective treatment strategy to restore endothelial
function. PRMT expression was increased in an animal
model ofCKD [82] and may be apotential therapeutictarget
to restore endothelial function.
DDAH converts ADMA to dimethylarginine and L-
citrulline and has been shown to decrease expression in
an animal model of CKD [82]. A useful method for
studying the role of ADMA in disease states is through
the modiﬁcation of DDAH enzyme expression in animal
models. In mice infected with recombinant DDAH, NO
synthesis was signiﬁcantly increased while plasma ADMA
concentrations were reduced compared to wild-type ani-
mals [85]. Endothelial-dependent relaxation was impaired
in streptozotocin-induced diabetic rats and restored by
overexpression DDAH [86]. When isolated mouse carotid
artery sections were transfected with recombinant DDAH
in the presence of exogenous ADMA, endothelial-dependent
relaxation was improved compared to uninfected vessels
[87]. ACE inhibition may also reduce ADMA levels and
contribute to improved endothelial function. One study
showed that 3 months of treatment with the ACE inhibitor
Ramipril (5mg/day) or the angiotensin II receptor antag-
onist Valsartan (160mg/day) reduced ADMA levels and
restored FMD in patients with nondiabetic CKD [26].
4.Conclusion
The endothelium represents the largest organ in the human
body and is vital for the maintenance of vascular homeosta-
sis.Thereisanurgentneedtounderstandthemechanisms by
which the endothelium becomes impaired in CKD in order
to design more eﬀective strategies for reducing cardiovascu-
larrisk.Chronickidneydiseaseisaworldwidehealthconcern
and leads to an accelerated risk of cardiovascular death.
Because there are a signiﬁcantly lower number of patients
with later stages of CKDlikely due to CVD-related death [3],
earlier stages of CKD should be more extensively studied in
order to better predict and prevent cardiovascular mortality
in CKD. There is limited but convincing data supporting
the role of endothelial dysfunction in earlier stages of CKD.
Future research should focus on better understanding the
mechanisms of endothelial dysfunction as well as develop-
mentofeﬀectiveinterventionsinearlierstagesofCKDwhere
the risk of cardiovascular death is most evident.
Evidence suggests that oxidative stress, L-arginine deﬁ-
ciency, and ADMA inhibition of NO synthesis all play roles
inthepathogenesisofendothelialdysfunctioninCKD.Based
upon diﬀerences between patients with ESRD and earlier
stages of CKD, it appears that there may be a point at
which endothelial dysfunction becomes less reversible with
advancing kidney disease [27]. Evidence from cell culture
studies linking the impaired transport of L-arginine to
uremictoxinssupportsthishypothesisandmay beappliedto
other mechanisms of endothelial dysfunction. The increased
uremic burden that accompanies late-stage CKD may trigger
a “uremic switch” resulting in endothelial dysfunction that is
less reversible due to an inability to transport L-arginine into
endothelial cells. Once triggered, conventional therapies for
treating endothelial dysfunction may become less eﬀective
leading to the increased prevalence of CVD seen in late-stage
CKD.Itisthereforenecessary tounderstandthepathogenesis
of endothelial dysfunction in earlier stages of CKD in order
to prevent the deterioration of vascular function.
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